Anti-CD38 Antibody Treating Evans Syndrome

Summary

A single-center, open-label, off-label use investigator-initiated clinical study with safety run-in to explore the clinical activity and safety of Anti-CD38 Antibody in adult ES patients who have not responded adequately or relapsed after first-line treatment and at least one second-line therapy including immunosuppressive agents, Anti-CD20 Antibody and/or TPO-RA, or those in whom no other second-line treatment options are suitable.

Timeline

Start

2023-12-01

Primary completion

2025-08

Completion

2025-08

Drugs

Indications